Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets
Launched by UNIVERSITY OF BRITISH COLUMBIA · May 22, 2009
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
This study seeks to determine whether HIV positive patients who have suboptimal lipids and/or are not reaching specified lipid targets will benefit from the addition of a second lipid lowering drug (ezetimibe) to existing lipid lowering therapy with a statin (specifically rosuvastatin) versus increasing the dose of the ongoing statin in terms of improvements in serum lipid parameters namely total cholesterol, LDL, HDL, triglycerides and apolipoprotein B100 (apoB), apolipoprotein A1 (apoA1), apoB/apoA1 ratio.
The target population will be HIV+ patients with hypercholesterolemia due to highl...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • HIV positive
- • currently taking 10mg of rosuvastatin
- • recent (within three months) fasting lipid profile in which the serum total cholesterol to HDL ratio is \>5.0
- Exclusion Criteria:
- • Previous adverse reaction to ezetimibe
- • taken ezetimibe within 30 days of starting the study
- • history of vascular disease
- • allergic reaction or muscle problems while taking any statin
- • currently taking other lipid lowering medications (i.e. a fibrates or cholestyramine)
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Greg Bondy, MD
Principal Investigator
University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials